Studies weight and obesity in adults with phenylketonuria
Looks at how common excess weight is in adults with phenylketonuria, and possible causes.
Plain-language title generated from the registry record
Registry title: Prevalence and Determinants of Obesity in PKU Patients
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Where in Switzerland
- Lausanne University HospitalLausanne, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christel Tran
- Trial code
- NCT07703020
- Record updated
- 14 July 2026
- Original description
This observational cross-sectional multicenter study aims to assess the prevalence of overweight and obesity in adult patients with phenylketonuria (PKU) and to identify associated risk factors. Adult PKU patients followed in metabolic centers in Switzerland and Austria will be evaluated using clinical data, laboratory parameters, and standardized questionnaires addressing diet, physical activity, and psychological factors. The study seeks to better understand contributors to weight gain in this population to inform preventive strategies.Read full original descriptionShow less
Phenylketonuria Associated With Obesity: a Cross-sectional Pilot Study on Prevalence and Possible Contributive Factors
This observational cross-sectional multicenter study aims to assess the prevalence of overweight and obesity in adult patients with phenylketonuria (PKU) and to identify associated risk factors. Adult PKU patients followed in metabolic centers in Switzerland and Austria will be evaluated using clinical data, laboratory parameters, and standardized questionnaires addressing diet, physical activity, and psychological factors. The study seeks to better understand contributors to weight gain in this population to inform preventive strategies.
Inclusion: Confirmed diagnosis of phenylketonuria (PKU) by biochemical and/or molecular testing; Age ≥ 18 years; Ability to provide written informed consent.
Exclusion: Pregnant or lactating women; Inability to follow the study procedures (e.g., due to language barriers); Eligible participants who refuse to be informed of any important health concern discovered during the study; Investigators, their family members, employees, or anyone with a personal link to the investigator other than a doctor-patient relationship.